ADMA Biologics (ADMA) is back in focus after recent analyst downgrades tied to allegations of Asceniv revenue channel stuffing, rising days' sales outstanding and accounts receivable, and criticism of the company’s public response.

The recent short report and analyst downgrades come after a difficult stretch for ADMA’s share price, with a 30 day share price return of a 24.02% decline and a year to date share price return of a 39.15% decline, even though the 5 year total shareholder return is very large.

If this kind of volatility has you comparing opportunities across the sector, it may be a good moment to scan a wider set of healthcare names through 35 healthcare AI stocks

So with analyst concerns pulling ADMA’s share price sharply lower yet the stock still trading at a large discount to published price targets, are you looking at a potential mispricing here, or is the market already adjusting for future growth?

Most Popular Narrative: 48% Undervalued

According to the most followed valuation narrative, ADMA Biologics' fair value sits well above the recent $10.88 close, which is why the stock screens as materially undervalued in that framework.

Reverse discounted cashflow at current TTM revenue of 383 MUSD at 35% FCF → 134 MUSD → revenue needs to grow 16%/y over next 10 years to justify current price (if ADMA gets to 1 BUSD of revenue by 2029 → growth of 21%/year) → currently undervalued

Curious what kind of revenue ramp, margins and future earnings multiple sit behind that fair value number? The narrative builds in ambitious but specific targets and a clear timeline.

Result: Fair Value of $20.93 (UNDERVALUED)

However, this hinges on ADMA sustaining its current revenue and margin profile while managing scrutiny around ASCENIV sales practices and any potential impact on future product demand.

Next Steps

Given the mixed sentiment around valuation and short reports, it may be useful to act promptly and evaluate the thesis against the full picture of risks and rewards through 2 key rewards and 2 important warning signs

Ready to hunt for more compelling ideas?

If ADMA has sharpened your thinking on risk and reward, do not stop here. Broaden your watchlist now and give yourself more options tomorrow.

• Target resilience first by checking companies in the solid balance sheet and fundamentals stocks screener (41 results) that can help anchor your portfolio when conditions get choppy.
• Seek value with discipline by scanning the 63 high quality undervalued stocks for businesses that pair quality fundamentals with prices that may leave room for upside.
• Add some punchy growth ideas by reviewing the 26 elite penny stocks with strong financials before the crowd starts paying closer attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.